News & Events

Takeda to invest €25m and create up to 70 new roles in a new facility at their Grange Castle site in Dublin

Minister of State at the Department of Enterprise and Innovation Pat Breen TD announced today that Takeda Pharmaceutical Company Limited (TSE: 4502) is to create up to 70 new jobs and invest €25m in the construction of a new regenerative medicine facility at its site in Grange Castle.

The investment by Takeda will expand their Grange Castle site’s existing footprint, with the construction of a new standalone modular cell therapy facility dedicated to manufacturing a novel stem cell therapy. The investment will also create 70 temporary construction jobs. The facility will be in commercial operation by 2021. This investment is supported by the Irish Government through IDA Ireland.

The largest pharmaceutical company in Japan, Takeda first set up operations in Ireland in 1997 manufacturing products for global markets. In 2002 Takeda chose Dublin as the location for its first active pharmaceutical ingredient (API) facility outside of Japan. In 2017 Takeda also announced a €40m investment in the construction of a stand-alone production facility for the manufacture of part of their Oncology portfolio at Grange Castle.

At a ground breaking ceremony to mark the start of construction of its new regenerative medicine facility Minister of State Pat Breen TD said, "The pharma industry makes a huge contribution to the Irish economy in terms of jobs and exports, and is one of the fastest growing sectors. Takeda's decision to invest in Ireland is a great win and vote of confidence in Ireland and it builds on our ongoing expansion of the sector here. I'm delighted that this investment will bring a further 70 jobs to the company's existing Clondalkin facility". Mr. Paul Keogh, Plant Director at Takeda Ireland Grange Castle said that the additional investment in Ireland demonstrates the confidence and commitment Takeda has in its Irish operation. “To be chosen as the first site to introduce this new technology platform to our manufacturing network is very exciting. The nature of this product and its process will bring us closer to the patient than ever before which is a responsibility that we take very seriously. We have a great team here in Ireland and are committed to continuing to put patients first through the timely manufacture and supply of high quality products from our site. The roles being created are in the areas of quality, manufacturing and engineering”

Commenting on the investment Martin Shanahan, CEO IDA Ireland said, “Ireland is a globally recognised centre of excellence in Life sciences due to the country’s strong regulatory track record and talent availability. Today’s investment by Takeda demonstrates their continued commitment to Ireland.  I wish the Takeda team every success as they continue to grow their operations in Ireland.”

Ends

For further information please contact please contact Press Office, D/Business, Enterprise and Innovation press.office@dbei.gov.ie or ph 6312200

About Takeda Ireland Ltd

Established in Ireland in 1997, Takeda in Bray, Co, Wicklow, manufactures solid oral dosage blockbuster drug products for the European, the U.S and Japanese markets. In Grange Castle, Co. Dublin, the plant develops and produces Active Pharmaceutical Ingredient’s from clinical trial stages through to launch and full commercialisation for global markets. Takeda Ireland Ltd currently employs over 400 people, who are committed to improving the quality of life for patients. This year Takeda Ireland Ltd has been selected as the only pharmaceutical company in Ireland, to receive the coveted Top Employer® status for 2018. This award recognises our outstanding values, culture and our ways of working.

Back to Top